Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.
about
Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical TrialsEmerging and future therapies for nonalcoholic steatohepatitis in adults.The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials.Dysregulation of redox pathways in liver fibrosis.Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver.Lack of Additive Effects of Resveratrol and Energy Restriction in the Treatment of Hepatic Steatosis in RatsEmerging roles of SIRT1 in fatty liver diseases.Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals.Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.Effects of resveratrol supplementation on risk factors of non-communicable diseases: A meta-analysis of randomized controlled trials.Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls.Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease.Resveratrol Attenuates Adriamycin-Induced Focal Segmental Glomerulosclerosis through C3aR/C5aR- Sphingosine Kinase 1 Pathway.The therapeutic potential of resveratrol: a review of clinical trials.Effects of Pharmacologic Dose of Resveratrol Supplementation on Oxidative/Antioxidative Status Biomarkers in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD
P2860
Q36112852-5158465C-9211-41A8-B5AB-7464995C1FD3Q38827586-08A363F4-A64E-46B9-B9E0-7E400B9E2FECQ38908273-103AC934-47B3-4FB8-8C93-CFC2DAAC99D4Q38937340-25E420DB-8144-4C80-AC3C-6D7B629D4B46Q39405429-35B83DE5-285B-4A22-99BB-39C40E6EE4BAQ41195335-242C5DF9-E23E-44B3-9F43-47B2396B2FAAQ41377073-65ABA093-FE86-42D3-B230-8A0627FAAA08Q47160560-86F3583B-8ECE-4067-8E68-A16CE491A0B4Q47192103-374BEAF4-2A2D-48A1-A612-F629F749E0DDQ47768938-EDD6F1DF-C7B4-4AB7-93C0-5A8C5509C841Q53758887-9F74C860-9AF0-4858-9714-DC72E8B29155Q54095552-E12DEF9B-C399-4BEF-9D27-61BFE249DFB5Q54151193-99E98ADE-1C40-4500-9641-8CBF74A667CDQ55151370-E3F5B295-E07C-4872-8D2E-C0EC34331876Q55709012-3833EE14-0EAF-4DE0-8FC1-8442463B7C05Q58753073-72E3E441-4697-4DEA-8DCB-AA2CD0360B66
P2860
Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Placebo-controlled, randomised ...... alcoholic fatty liver disease.
@en
type
label
Placebo-controlled, randomised ...... alcoholic fatty liver disease.
@en
prefLabel
Placebo-controlled, randomised ...... alcoholic fatty liver disease.
@en
P2093
P2860
P50
P1476
Placebo-controlled, randomised ...... alcoholic fatty liver disease.
@en
P2093
Holger Jon Møller
Kasper Thorsen
Marianne Kjær Poulsen
Martin Kreuzfeldt
Ylva Kristina Hellberg
P2860
P304
P356
10.3109/00365521.2015.1107620
P50
P577
2016-04-01T00:00:00Z